A Trial of Hetrombopag in Healthy and Hepatic Impairment Subjects

Summary

This is a single-dose, open-label, phase I clinical study evaluating the PK of hetrombopag in subjects with mild hepatic impairment (Child-Pugh Class A), subjects with moderate hepatic impairment (Child-Pugh Class B), as well as age-, weight-, and gender-matched subjects with normal hepatic function.

Timeline

Start

2020-09-28

Primary completion

2020-12-04

Completion

2020-12-04

Drugs

Indications